|Articles|October 31, 2022

Massive Bio Onboards Over 100,000 Cancer Patients

Massive Bio announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022. The Massive Bio platform matches cancer patients with relevant clinical trials using AI.

Read more about the platform and its enrollment here.

.



Related to this article

Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.